Aktivní účast
Registrace
- Zlevněná registrace do 8. července 2010
- Běžná registrace do 26. srpna 2010
- Online registrace
- 1. oznámení, program (PDF)
Program konference
Friday, 3 September 20108:15
Opening remarks
Session I: State-of-the-art in surgery
8:30
The art of radical surgery
David Harpole, MD
8:55
The art of minimal invasive surgery
Masahiro Tsuboi, MD
9:20
EBUS versus mediastinoscopy
Speaker invited
Session II: Tobacco and carcinogenesis
9:45
Tobacco control in Asia
Speaker invited
10:20
Carcinogenesis of lung cancer: Smoker vs non-smoker
Speaker invited
10:45
Coffee break
Session III: State-of-the-art radiotherapy
11:15
Novel radiotherapy technology
Speaker invited
11:40
Stereotactic radiotherapy for resectable lung cancer
Speaker invited
12:05 Stereotactic and respiratory gated radiotherapy: Local experience
Speaker invited
12:30
Panel discussion and cases
13:00
Lunch break
Keynote lecture
14:00
Clinical trial on molecular targeting agent: What is right and what is wrong?
Francis A. Shepherd, MD
Session IV: Gene signature and biomarkers
14:40
Gene signature for chemotherapy
Giorgio V. Scagliotti, MD, PhD
15:05 Metagene or magic gene
David Harpole, MD
15:30
Clinical application of biomarker in management of NSCLC
Speaker invited
15:55
Coffee break
Session V: Stage III disease
16:15
Optimal radiotherapy for stage III NSCLC
Speaker invited
16:40
Optimal combined modality for stage III NSCLC
Wilfrried Eberhardt, MD
17:05
Adjourn
Saturday 4 September 2010
Session VI: State of the art in chemotherapy
8:30
Novel development in cytotoxic chemotherapy
Speaker invited
8:55
Combination of chemotherapy with molecular target therapy: A good idea that is not so good
Tony Mok, MD
9:20
Patient selection for maintenance therapy
Speaker invited
Session VII: Novel targets
9:35
MAGE A3
Speaker invited
9:50
ELM-4 ALK
Tetsuya Mitsudomi, MD
10:05
IGF-R
Speaker invited
10:20
Irreversible EGFR TKI
Speaker invited
10:45
Vascular disrupting agent and VEGF TKIs
Nick Pavlakis, MD
11:00
Coffee break
Session VIII: State-of-the-art diagnosis
11:30
Florescence bronchoscopy and pleuroscopy for diagnosis of lung cancer
Speaker invited
11:55
PET-Scan, MRI, or CT scan: Which is a better tool for early/late stage NSCLC?
Speaker invited
12:05
Global view on first line management of advanced NSCLC
Speaker invited
12:40
Panel discussion and cases
13:15
Lunch break
Session IX: The unfinished EGFR story
14:15
Cost-effectiveness of EGFR TKI
Gilberto Lopes, MD
14:30
Detecting EGFR mutation in plasma: DHPLC
Speaker invited
14:45
Detecting EGFR mutation in plasma: Digital PCR
Speaker invited
15:00
EGFR TKI resistance
Lu Shun, MD
15:15
Pharmacokinetics of EGFR TKI and treatment outcome
Speaker invited
15:30
Coffee break
Session X: Research and development
15:50
The art and science of phase I study
Speaker invited
16:10
Getting published in a high impact journal
Speaker invited
16:20
Current status of lung cancer research in Asia
Sumitra Thongprasert, MD
Current status of lung cancer research in China
YL-Long Wu, MD
Current status of lung cancer research in Japan
Speaker invited
17:00
Closing remarks
Kontakt: meetings@imedex.com
Web: http://www.imedex...._Open5_5_2010&u
- Přidat do kalendáře: 2010-09-03 00:00:00 2010-09-04 23:59:59 Europe/Prague Fourth Asian Pacific Conference: Perspectives in Lung Cancer Hyatt Regency Hong Kong, Sha Tin, Hong Kong, China